Lung function and survival in systemic sclerosis interstitial lung disease

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2326-2328

  Ahmed, Samar Shadly ^a,b   Johnson, Sindhu R ^c,d   Meaney, Christopher ^d   Chau, Cathy ^c   Marras, Theodore K ^a,b,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c Toronto Scleroderma Program   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LETTER; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REFERENCE VALUE; SURVIVAL; SYSTEMIC SCLEROSIS; CAUSE OF DEATH; COMORBIDITY; COMPLICATION; KAPLAN MEIER METHOD; LUNG DISEASES, INTERSTITIAL; NONPARAMETRIC TEST; PROPORTIONAL HAZARDS MODEL; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; VITAL CAPACITY;

CAUSE OF DEATH; COMORBIDITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; LUNG DISEASES, INTERSTITIAL; MALE; PROPORTIONAL HAZARDS MODELS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; VITAL CAPACITY;

EID: 84923227540     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140156     Document Type: Letter

References (10)

1. Steen VD, Conte C, Owens G.R., Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37:1283-9.
2. Goh NS, Desai SR, Veeraraghavan S, Hansell D.M., Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248-54.
3. Simeon C, Armadans L, Fonollosa V., Solans R, Selva A, Villar M., et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003; 42:71-5.
4. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437-44.
5. Morgan C, Knight C, Lunt M., Black C, Silman A. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003; 62:146-50.
6. Scussel-Lonzetti L, Joyal F, Raynauld J.P., Roussin A., Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81:154-67.
7. Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
8. Johnson SR, Granton JT, Tomlinson G.A., Grosbein HA, Le T, Lee P, et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 2012; 39:276-85.
9. Lausen B, Hothom T, Bretz F., Schumacher M. Assessment of optimal selected prognostic factors. Biom J 2004; 46:364-74.
10. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. Classification criteria for systemic sclerosis: An ACR-EULAR collaborative initiative. Arthritis Rheum 2013; 65:2737-47.